The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors
https://doi.org/10.17650/1818-8346-2019-14-4-84-89
Abstract
Oncolytic viruses are promising agents for the treatment of various types of tumors, including malignant non-Hodgkin lymphomas. In order to identify the most effective candidates from a wide panel of non-pathogenic antitumor strains, a study was carried out of their ability to reproduce in short-term cultures of lymphoid tumor cells. Also, tumor cell cultures were characterized in relation to the presence of specific viral receptors CD54, CD55, CD155 on their surface.
Supporting agencies: The study was supported by the grant No 1.1096 from the Ministry of Health of Russia, and the grant No 075-15-2019-1660 to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine under Federal Research Programme for Genetic Technologies Development for 2019-2027
About the Authors
F. E. Babaeva
National Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Novyy Zykovskiy Proezd, Moscow 125167
A. V. Lipatova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Russian Federation
Russian Federation
32 Vavilova St., Moscow 119991
D. V. Kochetkov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Russian Federation
Russian Federation
32 Vavilova St., Moscow 119991
P. M. Chumakov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Russian Federation
Russian Federation
32 Vavilova St., Moscow 119991
S. K. Kravchenko
National Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Novyy Zykovskiy Proezd, Moscow 125167
References
1. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the nonHodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Project Ann Oncol 1998;9(7):717—20.
2. Phan M., Watson M.F., Alain T., Diallo J.S. Oncolytic viruses on drugs: achieving higher therapeutic efficacy. ACS Infect Dis 2018;4(10):1448—67. DOI: 10.1021/acsinfecdis.8b00144.
3. Luminari S., Bellei M., Biasoli I., Federico M. Follicular lymphoma — treatment and prognostic factors. Rev Bras Hematol Hemoter 2012;34(1):54—9. DOI: 10.5581/1516-8484.20120015.
4. Magomedova A.U. Diffusive large B-cell lymphosarcoma of lymphoid organs: clinical forms, treatment. Thesis . of doctor of medical sciences. Moscow, 2008. Рр. 183-5. (In Russ).
5. Ungerechts G., Frenzke M.E., Yaiw K.C. et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Therapy 2010;17(12):1506-16. DOI: 10.1038/gt.2010.103.
6. Heinzerling L., Kttnzi V., Oberholzer P.A. et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005;106(7):2287-94. DOI: 10.1182/blood-2004-11-4558.
7. Hanauer J.D.S., Rengstl B., KleinlUtzum D. et al. CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma. Oncotarget 2018;9(16):12971 — 81. DOI: 10.18632/oncotarget.24191.
8. Namba M., Kimoto T. Culture conditions for a human lymphoma cell line (Raji) and their application to mutation research. Gan 1981;72(3):459—63.
9. Minowada J., Ohnuma T., Moore G.E. Rosette-forming human lymphoid lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Nat Cancer Inst 1972;49(3):891—5.
10. Nilsson K. Human B-lymphoid cell lines. Hum Cell 1992;5(1):25—41.
11. Voroshilova M.K., Goryunova A.G., Gorbachkova E.A. et al. The study of cellular immunity in cancer patients during asymptomatic enterovirus infection. In: Virotherapy and artificial tumor heterogenization. Zinatne, Riga, 1977; Pp. 17-19. (In Russ.).
12. Chumakov P.M., Morozova V.V., Babkin I.V et al. Oncolytic enteroviruses. Molekulyarnaya biologiya = Molecular Biology 2012;46:712-25. (In Russ.).
13. Blackham A.U., Northrup S.A., Willingham M. et al. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res 2014;187(2):412—26. DOI: 10.1016/j.jss.2013.10.032.
14. Betancourt D.M. Vesicular stomatitis virus is a malleable oncolytic vector for the treatment of various malignancies. University of Miami, 2017.
15. Balachandran S., Barber G.N. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004;5:51—65.
16. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hygiene 1938;27:493—7.
17. Lipatova A.V., Le T.H., Sosnovtseva A.O. et al. Relationship between cell receptors and tumor cell sensitivity to oncolytic enteroviruses. Bull Exp Biol Med 2018;166(1):58—62. DOI: 10.1007/s10517-018-4289-1.
18. Soboleva A.V., Seryak D.A., Gabdrakhmanova A.F. et al. Glioblastoma Multiforme stem cells are highly sensitive to some human non-pathogenic enteroviruses. J Pharm Sci Res 2018;10(4):936—9.
19. Sidorenko A.S., Zheltukhin A.O., Le T.H. et al. Persistence of oncolytic coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy. Bulletin of Russian State Medical University, 2018. Pp. 41-46.
20. Soboleva A.V., Lipatova A.V., Kochetkov D.V., Chumakov P.M. Changes in the sensitivity of human glioblastoma cells to oncolytic enteroviruses induced by passaging. Bulletin of Russian State Medical University, 2018. Pp. 37-41.
21. Svyatchenko V.A., Ternovoy V.A., Kiselev N.N. et al. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines. Arch Virol 2017;162(11):3355-62. DOI: 10.1007/s00705-017-3492-0.
22. Ohka S., Nihei C.I., Yamazaki M., Nomoto A. Poliovirus trafficking toward central nervous system via human poliovirus receptor-dependent and-independent pathway. Front Microbiol 2012;3:147-51. DOI: 10.3389/fmicb.2012.00147.
Review
For citations:
Babaeva F.E., Lipatova A.V., Kochetkov D.V., Chumakov P.M., Kravchenko S.K. The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors. Oncohematology. 2019;14(4):84-89. (In Russ.) https://doi.org/10.17650/1818-8346-2019-14-4-84-89
Views:
9655
Email this article 